A new tactile skin sensor for measuring skin hardness in patients with systemic sclerosis and autoimmune Raynaud's phenomenon.
We used a new tactile sensor to measure the elastic properties of skin in patients with systemic sclerosis or Raynaud's phenomenon. The sensor consists of a piezoelectric vibrator with vibration pickup to measure frequency changes when the sensor is placed on the skin. The mean frequency change at the skin surface of the proximol third phalanx in patients with systemic sclerosis was significantly lower than in age- and sex-matched controls. The results in systemic sclerosis patients were statistically correlated to the Modified Rodnan Skin Thickness Score. This technique was also used to measure the therapeutic efficacy of salpogrelate, a new specific serotonin receptor antagonist. A greater mean frequency change was seen after treatment. We conclude that this new tactile sensor is useful for quantitatively measuring skin sclerosis and may help determine the efficacy of therapeutic treatments.
Takei
M
M
First Division of Internal Medicine, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Shiraiwa
H
H
Omata
S
S
Motooka
N
N
Mitamura
K
K
Horie
T
T
Ookubo
T
T
Sawada
S
S
D001555:Benzene Derivatives / Q000627:therapeutic use; D006801:Humans; D008991:Monitoring, Physiologic / Q000295:instrumentation*; D011928:Raynaud Disease / Q000188:drug therapy / Q000503:physiopathology*; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000503:physiopathology*; D012702:Serotonin Antagonists / Q000627:therapeutic use; D012867:Skin / Q000503:physiopathology*; D016896:Treatment Outcome
D001555:Benzene Derivatives; D012702:Serotonin Antagonists